Top Biopharma Deal March 2021: Debiopharm – Merck KGaA for Xevinapant for head and neck cancer
Highlighted Deal Financial Comps
Total Deal Value:
Cost & Profit Split:
- Debiopharm granted Merck exclusive, worldwide rights to develop and commercialize Xevinapant for the treatment of advanced squamous cell carcinoma of the head and neck.
- Both companies will co-fund the ongoing Phase III registrational TrilynX study.
- Debiopharm will receive EUR 188M ($227M) up front and is eligible to receive up to EUR 710M ($856M) in regulatory and commercial milestones, plus royalties.
Congrats to Debiopharm and Merck KGaA for landing the DealForma March 2021 Top Biopharma Deal of the Month. The Deal of the Month for February 2021 was the Vir – GSK expansion in to influenza. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
Drug Sales Figures
All of this by stage, disease indication, modality, target...
More Research by DealForma
Introducing: DealForma plus Tableau
We are excited to introduce DealForma's new Tableau dashboard integration. High quality data on biopharma deals and funding meets interactive charts and visuals. DealForma customers will have exclusive access to the DealForma chart dashboards built on Tableau right...
Venture & IPO – Medtech – Q1 2023
The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...